1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,596 | 1,640 | 12:16 | |
| 1,612 | 1,642 | 12:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 173 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 319 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 133 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 129 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 383 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 315 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 300 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 180 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 252 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 254 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen | |
| 31.10.25 | SynAct Pharma - Approaching a catalyst-rich period | 378 | Edison Investment Research | SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid... ► Artikel lesen | |
| 30.10.25 | SynAct Pharma AB: SynAct Pharma publishes Q3 2025 interim results | 193 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2025.
"SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune... ► Artikel lesen | |
| 28.10.25 | SynAct Pharma - Differentiated inflammation resolution approach | 333 | Edison Investment Research | SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to... ► Artikel lesen | |
| 16.09.25 | SynAct Pharma AB: SynAct Pharma's CFO Björn Westberg leaves for new leading position | 191 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company's... ► Artikel lesen | |
| 05.09.25 | SynAct Pharma AB: SynAct appoints Mads Bjerregaard as Chief Business Officer | 234 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Mads... ► Artikel lesen | |
| 20.08.25 | SynAct Pharma AB: SynAct Pharma publishes Q2 2025 interim results | 268 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2025.
"SynAct continued to strengthen its position during the second quarter, refining its development strategy... ► Artikel lesen | |
| 27.05.25 | SynAct Pharma AB: SynAct Pharma publishes Q1 2025 interim results | 295 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2025.
"SynAct Pharma has a remarkable drug candidate with resomelagon (AP1189). The data gained so far point... ► Artikel lesen | |
| 12.05.25 | SynAct Pharma AB: SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy | 451 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has provided the issue notification of US patent 12,303,489 with issue date 20 May 2025... ► Artikel lesen | |
| 23.04.25 | SynAct Pharma AB: SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy | 265 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application US 17/609,849 with claims covering... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,710 | -0,07 % | Bayer: Das könnte zum Problem werden | Die Bayer-Aktie zeigt nach einer Erholung zuletzt wieder mehr Gegenwind im Chartbild. Im Fokus steht nun, ob sich die Erholung fortsetzen kann oder der Druck zunimmt Den vollständigen Artikel lesen... ► Artikel lesen | |
| NOVO NORDISK | 34,915 | +1,16 % | Novo Nordisk: Offensive im Abnehm-Markt - und ein Vorteil im Datencheck | Novo Nordisk drückt weiter aufs Gaspedal. Das Unternehmen hat die nächste Ausbaustufe seines Abnehm-Blockbusters an den Start gebracht: Seit Dienstag ist in den USA die neue Hochdosis-Variante Wegovy... ► Artikel lesen | |
| MERCK KGAA | 115,65 | -1,28 % | Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen | DJ Eon will Heidelberg-Materials-Chef und Merck-Finanzchefin in den Aufsichtsrat holen
DOW JONES--Der Netzbetreiber Eon will zwei hochrangige Manager in seinen Aufsichtsrat holen. Die Hauptversammlung... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,500 | 0,00 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| PFIZER | 23,100 | +0,26 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| NOVARTIS | 127,50 | -1,02 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis mit einem Kursziel von 116 Franken auf "Neutral" belassen. Mit seinen Schätzungen für Umsatz und operatives Ergebnis... ► Artikel lesen | |
| LB PHARMACEUTICALS | 29,115 | +9,58 % | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | ||
| ELI LILLY | 772,80 | +0,74 % | SAP weiter unter Beschuss, Amazon verspricht hohe KI-Umsätze, Eli Lilly schmiedet neue Partnerschaft und TUI sagt weitere Kreuzfahrten ab | Aus dem ganz großen Turnaround ist an der Börse erstmal nichts geworden. Zu brüchig ist die Waffenruhe im Nahen Osten. Bis jetzt hat sie zwar gehalten, doch scheinen gleichzeitig nur wenige Schiffe... ► Artikel lesen | |
| OMNIAB | 1,480 | 0,00 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 2,195 | 0,00 % | Milestone Pharmaceuticals initiiert Real-World-Studie für PSVT-Medikament CARDAMYST | ||
| ATRIUM THERAPEUTICS | 14,530 | 0,00 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 26,970 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GRACE THERAPEUTICS | 4,360 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 | PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen | |
| CANOPY GROWTH | 0,971 | -0,84 % | Nach den Tilray-Zahlen: Aurora, Canopy & Co. vor richtungsweisender Berichtssaison | In einer Phase, in der sich das Handelsgeschehen auf die Auswirkungen des Iran-Krieges zu konzentrieren scheint, nimmt die Quartalsberichtssaison Fahrt auf. Für die Cannabis-Unternehmen wird es möglicherweise... ► Artikel lesen | |
| SCHOTT PHARMA | 14,840 | +1,09 % | SCHOTT PHARMA AG & CO KGAA - Stabilität als Fundament |
SYNACT PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,628 Euro und damit +0,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.